Document Detail

Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
MedLine Citation:
PMID:  22261365     Owner:  NLM     Status:  Publisher    
OBJECTIVE: Previous studies have shown that visfatin is significantly elevated in patients with gastric carcinoma and postmenopausal breast cancer (PBC). We thus explored whether serum visfatin could be used as a potential diagnostic and prognostic tool for PBC, taking into account clinicopathological features, serum tumor markers, anthropometric and metabolic parameters. METHODS: Serum visfatin, tumor marker CA 15-3, carcinoembryonic antigen, metabolic and anthropometric parameters were determined in 103 postmenopausal women with pathologically confirmed, incident invasive breast cancer, 103 controls matched on age and time of diagnosis, and 51 patients with benign breast lesions (BBL). RESULTS: Mean serum visfatin was significantly higher in cases than in controls and patients with BBL (p<0.001). In cases, visfatin was significantly associated with CA 15-3 (p=0.03), hormone-receptor status (p<0.001), lymph node invasion (p=0.06) but not with metabolic and anthropometric variables (p>0.05). Multivariable regression analysis revealed that absence of estrogen and progesterone receptors (ER-PR-) was the strongest significant determinant of serum visfatin (p<0.001) in cases adjusting for demographic, metabolic and clinicopathological features. Based upon receiver operator characteristic analysis, serum visfatin outperformed CA 15-3 only in discriminating between PBC cases with early cancer stage than those with late stage, and in differentiating particularly patients with ER-PR- breast tumors. CONCLUSION: Further prospective and longitudinal studies are needed to determine whether serum visfatin could be used as a prognostic tool in the armamentarium of PBC monitoring and management in conjunction with other biomarkers.
Maria Dalamaga; Stavros Archondakis; George Sotiropoulos; Konstantinos Karmaniolas; Nicolaos Pelekanos; Evangelia Papadavid; Antigoni Lekka
Related Documents :
21700955 - Dna methylation of tumor suppressor and metastasis suppressor genes in circulating tumo...
21362365 - Polymorphisms of gstp1 is associated with differences of chemotherapy response and toxi...
21898115 - Aspirin use and breast cancer risk: a meta-analysis.
21714875 - Male breast cancer: a report of 127 cases at a moroccan institution.
2434935 - Biosynthesis and localization of inhibin in human prostate.
9825835 - Susceptibility and outcome in oral cancer: preliminary data showing an association with...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-17
Journal Detail:
Title:  Maturitas     Volume:  -     ISSN:  1873-4111     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7807333     Medline TA:  Maturitas     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Department of Clinical Biochemistry, Medical School, University of Athens, "Attikon" General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece; Laboratory Department, NIMTS-Army Share Fund General Hospital, 12 Monis Petraki and Vasilissis Sofias Avenue, 11528 Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preplaque ('Preclinical') A?-Induced Inflammation and Nerve Growth Factor Deregulation in Transgenic...
Next Document:  Nanomedicine for the prevention, treatment and imaging of atherosclerosis.